trospium chloride

(redirected from Trospium)
Also found in: Medical, Wikipedia.
Related to Trospium: Trospium chloride, Sanctura
Translations

trospium chloride

n cloruro de trospio
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
The anticholinergics segment has been further sub-segmented into solifenacin, oxybutynin, fesoterodine, darifenacin, tolterodine, trospium, and others.
Darifenacin (Enablex), fesoterodine (Toviaz), flavoxate (Urispas), oxybutynin (Ditropan), solifenacin (Vesicare), tolterodine (Detrai), and trospium (Sanctura).
KarXT, a proprietary oral modulator of muscarinic receptors, is the Company's lead product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the central nervous system (CNS).
Basic characteristics of the antimuscarinic drugs Darifenacin 507.5 Low M3 Fesoterodine 527.6 Low Non-selective Oxybutynin 393.9 High Non-selective Propiverine 403.9 (*) Limited data Non-selective Solifenacin 480.5 Moderate Predominantly M3 Tolterodine 475.6 Moderate Non-selective Trospium 427.9 Low Non-selective BBB: Blood-brain barrier, (*) Value expressed in g/moL Table 2.
The company offers KarXT that targets the muscarinic acetylcholine receptors for the treatment of schizophrenia and is composed of xanomeline, a novel clinical-stage muscarinic acetylcholine receptor agonist (activator); and trospium chloride, an FDA-approved muscarinic receptor antagonist (blocker) that has been shown not to enter the central nervous system.
(6) Currently in Canada there are six anticholinergic drugs approved for treatment of OAB symptoms: darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine and trospium. Three (darifenacin, fesoterodine and mirabegron) of these were approved in the last 10 years.
Darifenacin, mirabegron, oxybutynin ER, solifenacin, tolterodine, and trospium were classified as FORTA C (Questionable; Caution), while oxybutynin IR and propiverine were classified as FORTA D (Avoid; Do not).
Two hundred forty-one women with moderate to severe UUI received either 6 months of oral anticholinergic therapy (solifenacin 5 mg daily with the option of dose escalation to 10 mg daily or change to trospium XR 60 mg daily based on the Patient Global Symptom Control score) plus a single intradetrusor injection of saline, or a single intradetrusor injection of onabotulinumtoxinA 100 U plus a 6-month oral placebo regimen.
The DDS, which releases the anticholinergic agent trospium chloride, can be applied into the bladder through the urethra.
Some drugs to watch out for include the following (and their generics): diphenhydramine (Benadryl); certain antidepressants, such as amitriptyline; some diuretics and other drugs for high blood pressure, including losartan (Cozaar) and valsartan (Diovan); and drugs for an overactive bladder, such as oxybutynin (Ditropan), solifenacin (VESIcare) and trospium (Sanctura).